Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MRVI
stocks logo

MRVI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
49.03M
-13.31%
-0.070
+16.95%
50.60M
+8%
-0.053
-33.86%
49.41M
+4.26%
-0.052
-34.55%
Estimates Revision
The market is revising Downward the revenue expectations for Maravai LifeSciences Holdings, Inc. (MRVI) for FY2025, with the revenue forecasts being adjusted by -3.69% over the past three months. During the same period, the stock price has changed by 47.41%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.18%
In Past 3 Month
Stock Price
Go Up
up Image
+47.41%
In Past 3 Month
Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.700
sliders
Low
4.00
Averages
4.50
High
5.00
Current: 3.700
sliders
Low
4.00
Averages
4.50
High
5.00
Stifel
Buy
downgrade
$5 -> $4
2025-11-07
Reason
Stifel
Price Target
$5 -> $4
2025-11-07
downgrade
Buy
Reason
Stifel lowered the firm's price target on Maravai Lifesciences to $4 from $5 and keeps a Buy rating on the shares. Maravai posted a Q3 miss with revenue of $42M coming in below the $50M consensus view, the analyst tells investors in a research note. The firm added that Maravai looks "fairly washed out" at the $2-$3 level, but with a new management team and low visibility, the shares are appropriate for only the intrepid right now.
Craig-Hallum
Buy
downgrade
$10 -> $5
2025-08-12
Reason
Craig-Hallum
Price Target
$10 -> $5
2025-08-12
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on Maravai Lifesciences to $5 from $10 and keeps a Buy rating on the shares. The company announced a new plan to turn things around. The company plans to cut $50M in annual spending through headcount reductions and spending cuts across all departments. With changes occurring gradually over the next 12 months, management plans to decrease the expense run rate through FY26, the firm notes.
RBC Capital
Outperform
to
NULL
downgrade
$7 -> $5
2025-08-12
Reason
RBC Capital
Price Target
$7 -> $5
2025-08-12
downgrade
Outperform
to
NULL
Reason
RBC Capital lowered the firm's price target on Maravai Lifesciences to $5 from $7 and keeps an Outperform rating on the shares after its Q2 earnings miss. With the new management in place and FY25 guidance suspended however, Maravai is on a path to rationalizing its cost structure, starting with $50M in cost actions with aims to return to adjusted EBITDA positive by the second half of FY26, the analyst tells investors in a research note.
Baird
Catherine Ramsey Schulte
Neutral
downgrade
$3 -> $2
2025-05-13
Reason
Baird
Catherine Ramsey Schulte
Price Target
$3 -> $2
2025-05-13
downgrade
Neutral
Reason
Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Maravai Lifesciences to $2 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where revenue beat and guidance is maintained for 2025.
Craig-Hallum
Matt Hewitt
Buy
downgrade
$12 -> $10
2025-05-13
Reason
Craig-Hallum
Matt Hewitt
Price Target
$12 -> $10
2025-05-13
downgrade
Buy
Reason
Craig-Hallum analyst Matt Hewitt lowered the firm's price target on Maravai Lifesciences to $10 from $12 and keeps a Buy rating on the shares following quarterly results. The firm noted that investors should take a closer look at the company, as they are well-positioned to benefit from the industry's shift toward repatriation of pharma manufacturing and the FDA's new AI/modeling initiative-driving demand for the company's specialized products and services.
Morgan Stanley
Tejas Savant
Hold
Maintains
$7 → $5
2025-03-25
Reason
Morgan Stanley
Tejas Savant
Price Target
$7 → $5
2025-03-25
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Maravai LifeSciences Holdings Inc (MRVI.O) is -16.40, compared to its 5-year average forward P/E of 1165.74. For a more detailed relative valuation and DCF analysis to assess Maravai LifeSciences Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
1165.74
Current PE
-16.40
Overvalued PE
6016.75
Undervalued PE
-3685.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
79.15
Undervalued EV/EBITDA
-95.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.33
Current PS
0.00
Overvalued PS
6.07
Undervalued PS
2.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MRVI News & Events

Events Timeline

(ET)
2025-11-06
16:02:43
Maravai Lifesciences announces Q3 adjusted EPS of 8 cents, matching consensus expectations.
select
2025-08-11 (ET)
2025-08-11
16:44:51
Maravai Lifesciences withdraws FY25 guidance
select
2025-08-11
16:43:48
Maravai Lifesciences reports Q2 adjusted EPS (8c), consensus (7c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
10-29Globenewswire
Reminder: Bragar Eagel & Squire, P.C. Ongoing Investigation for Maravai Long-Term Shareholders

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. (MRVI) for long-term stockholders who experienced losses between August 7, 2024, and February 24, 2025, following a class action complaint filed on March 3, 2025.

  • Company Issues: Maravai announced a delay in its fiscal 2024 earnings release due to an error in revenue recognition and identified a material weakness in its internal controls, leading to a significant drop in share price.

  • Allegations: The class action complaint alleges that Maravai's board made misleading statements and failed to disclose critical information regarding the company's financial reporting and goodwill, which misled investors about its business prospects.

  • Contact Information: Long-term stockholders with information or questions are encouraged to contact Bragar Eagel & Squire, P.C. directly via phone or email for further assistance regarding their legal rights.

[object Object]
Preview
4.5
10-08NASDAQ.COM
ETF Movers on Tuesday: FIG, ITB

  • iShares U.S. Home Construction ETF Performance: The iShares U.S. Home Construction ETF is down approximately 2.8% in Tuesday afternoon trading, underperforming other ETFs.

  • Weakest Components: Notable declines among ETF components include D.R. Horton, which fell about 5.3%, and Century Communities, which decreased by about 5.1%.

[object Object]
Preview
7.0
10-02Globenewswire
Investigation Notice: Bragar Eagel & Squire, P.C. Informs Long-Term Stockholders of Maravai LifeSciences Holdings, Inc. and Invites Investors to Reach Out to the Firm

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences (MRVI) for long-term stockholders who purchased shares between August 7, 2024, and February 24, 2025, following a class action complaint filed on March 3, 2025.

  • Company Issues: Maravai announced a delay in its fiscal 2024 earnings release due to a revenue recognition error and identified weaknesses in its internal controls, leading to a significant drop in share price and allegations of misleading statements by the company's board.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Maravai LifeSciences Holdings Inc (MRVI) stock price today?

The current price of MRVI is 3.7 USD — it has increased 5.41 % in the last trading day.

arrow icon

What is Maravai LifeSciences Holdings Inc (MRVI)'s business?

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

arrow icon

What is the price predicton of MRVI Stock?

Wall Street analysts forecast MRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRVI is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Maravai LifeSciences Holdings Inc (MRVI)'s revenue for the last quarter?

Maravai LifeSciences Holdings Inc revenue for the last quarter amounts to 41.63M USD, decreased -39.69 % YoY.

arrow icon

What is Maravai LifeSciences Holdings Inc (MRVI)'s earnings per share (EPS) for the last quarter?

Maravai LifeSciences Holdings Inc. EPS for the last quarter amounts to -0.18 USD, decreased -73.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Maravai LifeSciences Holdings Inc (MRVI)'s fundamentals?

The market is revising Downward the revenue expectations for Maravai LifeSciences Holdings, Inc. (MRVI) for FY2025, with the revenue forecasts being adjusted by -3.69% over the past three months. During the same period, the stock price has changed by 47.41%.
arrow icon

How many employees does Maravai LifeSciences Holdings Inc (MRVI). have?

Maravai LifeSciences Holdings Inc (MRVI) has 570 emplpoyees as of December 05 2025.

arrow icon

What is Maravai LifeSciences Holdings Inc (MRVI) market cap?

Today MRVI has the market capitalization of 945.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free